Last reviewed · How we verify
NCT06728917: OBILART
Occult Hepatitis B Virus Infection and HBV Reactivation After Switching to Long Acting Therapy in Patients With HIV-1
trial in HBV (Hepatitis B Virus) in 50 participants. Not yet recruiting.
30 April 2025
Quick facts
| Lead sponsor | IRCCS San Raffaele |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 20 January 2025 |
| Primary completion | 30 April 2025 |
| Estimated completion | 30 November 2025 |
| Sites | 3 locations across Italy |
Conditions studied
- HBV (Hepatitis B Virus) — all drugs for HBV (Hepatitis B Virus) →
- HIV Infection — all drugs for HIV Infection →
Sponsor
IRCCS San Raffaele — full company profile →
Who can join
18 and older, any sex, with HBV (Hepatitis B Virus) or HIV Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of the present project will be to investigate the risk of HBV reactivation (from virological reactivation to overt HBV infection) in HIV-1 carriers with occult HBV infection (OBI, is characterized by the absence of surface antigenemia, HBsAg negativity, with the presence of HBV-core antibody, HBcAb) and switching from antiretroviral therapy (ART) including nucleos(t)ides to long-acting formulation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06728917
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HBV (Hepatitis B Virus)
Currently open trials in the same condition.
- NCT07275554 — Analysis of Methylomic Features and Prognostic Risk Prediction in Patients With Hepatitis B-related Acute-on-chronic Liv · recruiting
- NCT07137247 — Immune Dynamics in the Natural History of Chronic HBV Infection · recruiting
Other IRCCS San Raffaele trials
Trials by the same sponsor.
- NCT07454759 — Acute Sarcopenia in Hospitalized Older Adults · not yet recruiting
- NCT07456462 — Making Antibody Treatments More Effective in Early Alzheimer's Disease Using 3Tesla Magnetica Resonance · NA · not yet recruiting
- NCT07066878 — This Protocol Focuses on the Factors That Influence Survival, the Development of Complications and the Quality of Life B · not yet recruiting
- NCT07526298 — Anticipating Irreversible Disability in Neuromyelitis Optica Spectrum Disorder: a Study to Assess Disease Activity in Ap · not yet recruiting
- NCT07426471 — Delafloxacin Plasma and Tissue Concentration in Patients With Skin, Soft Tissue, and Bone and Joint Infections. · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06728917 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by IRCCS San Raffaele
- Last refreshed: 11 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06728917.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing